Epidemiological aspects of neoplasms in diabetes

[1]  A. Wolff,et al.  Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2010, Digestive Diseases and Sciences.

[2]  A. Wolff,et al.  Does pre-existing diabetes affect prostate cancer prognosis? A systematic review , 2010, Prostate Cancer and Prostatic Diseases.

[3]  R. Vigneri.  Diabetes: Diabetes therapy and cancer risk , 2009, Nature Reviews Endocrinology.

[4]  D. Balzi,et al.  Sulphonylureas and cancer: a case–control study , 2008, Acta Diabetologica.

[5]  P. Home,et al.  Combined randomised controlled trial experience of malignancies in studies using insulin glargine , 2009, Diabetologia.

[6]  I. Hirsch,et al.  Insulin glargine and cancer--an unsubstantiated allegation. , 2009, Diabetes technology & therapeutics.

[7]  L. Smeeth,et al.  Insulin glargine and malignancy: an unwarranted alarm , 2009, The Lancet.

[8]  Manal M. Hassan,et al.  Antidiabetic therapies affect risk of pancreatic cancer. , 2009, Gastroenterology.

[9]  P. Goodwin,et al.  Metformin in breast cancer: time for action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[12]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[13]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[14]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[15]  M. Cazzaniga,et al.  Is it Time to Test Metformin in Breast Cancer Clinical Trials? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[16]  C. Tseng,et al.  Age-related risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in Taiwan , 2009, Annals of medicine.

[17]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[18]  J. Mitri,et al.  Diabetes and Risk of Non-Hodgkin's Lymphoma , 2008, Diabetes Care.

[19]  Yoshiyuki Suzuki,et al.  Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis , 2008, Journal of gastroenterology and hepatology.

[20]  N. Marchionni,et al.  Rosiglitazone and Risk of Cancer , 2008, Diabetes Care.

[21]  D. Balzi,et al.  Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality , 2007, Diabetes/metabolism research and reviews.

[22]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[23]  B. Littenberg,et al.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System , 2007, BMC medicine.

[24]  C. Mantzoros,et al.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.

[25]  N. Qizilbash,et al.  Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents , 2007, Pharmacoepidemiology and drug safety.

[26]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Beral,et al.  Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis , 2007, British Journal of Cancer.

[28]  E. Giovannucci,et al.  A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[29]  S. Larsson,et al.  Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.

[30]  Mitsuhiko Noda,et al.  Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. , 2006, Archives of internal medicine.

[31]  A. Belfiore,et al.  Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. , 2006, Endocrinology.

[32]  J. Klenk,et al.  Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria , 2006, Diabetologia.

[33]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[35]  D. Albanes,et al.  Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. , 2005, JAMA.

[36]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[37]  N. Waugh,et al.  Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study , 2005, British Journal of Cancer.

[38]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[39]  M. Kubo,et al.  Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. , 2005, Diabetes care.

[40]  R O Morgan,et al.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.

[41]  Siegal Sadetzki,et al.  Diabetes mellitus and breast cancer. , 2005, The Lancet. Oncology.

[42]  A. Folsom,et al.  Diabetes as a risk factor for death following endometrial cancer. , 2004, Gynecologic oncology.

[43]  Richard Kahn,et al.  Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association , 2004, Stroke.

[44]  Ted Gansler,et al.  Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association * † , 2004, Circulation.

[45]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[46]  N. Day,et al.  Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  M. Stampfer,et al.  A prospective study of plasma C-peptide and colorectal cancer risk in men. , 2004, Journal of the National Cancer Institute.

[48]  H. Adami,et al.  Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. , 2003, Journal of the National Cancer Institute.

[49]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[50]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[51]  E. Bonora,et al.  Mortality from site-specific malignancies in type 2 diabetic patients from Verona. , 2003, Diabetes care.

[52]  C. Ko,et al.  The need for a multidisciplinary approach to cancer care. , 2002, The Journal of surgical research.

[53]  H. Adami,et al.  Role of diabetes mellitus in the etiology of hepatocellular carcinoma. , 2000, Journal of the National Cancer Institute.

[54]  J. Poulson.  The management of diabetes in patients with advanced cancer. , 1997, Journal of pain and symptom management.

[55]  Sandra D Fights,et al.  Nurses' Health Study. , 2011, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[56]  E. López-Bonet,et al.  Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  F. Ovalle.  Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16 , 2010 .

[58]  E. Gale,et al.  4 The influence of glucose-lowering therapies on cancer risk , 2009 .

[59]  F. Ovalle.  10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[60]  the Scottish Diabetes Research Network Epidemiology Group.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[61]  P. Goodwin,et al.  Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 300(23):2754-64. PMID: 19088353 , 2009 .

[62]  J. Stockman.  Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women , 2006 .

[63]  L. Pollack,et al.  Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer , 2005, Nature Clinical Practice Oncology.

[64]  Cancer survivorship--United States, 1971-2001. , 2004, MMWR. Morbidity and mortality weekly report.